12:00 AM
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Nektar preclinical data

In a mouse model of melanoma, IV NKTR-214 given once every 9 days reduced mortality by 84% and delayed tumor growth vs. twice-daily aldesleukin. NKTR-214 also led to an 8-fold increase in CD8+ effector memory T cells...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >